Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationMechanisms of the Age-Associated Deterioration in Glucose Tolerance
Basu, R., Breda, E., Oberg, A. L., Powell, C. C., Dalla Man, C., Basu, A., Vittone, J. L., Klee, G. G., Arora, P., Jensen, M. D., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1738 · Cited by 440 · cited 1×
“Since elderly subjects have been reported to have significantly higher plasma glucagon levels than younger people [15], vildagliptin-mediated suppression of inappropriate glucagon secretion may contribute to the greater efficacy observed in elderly as compared with younger patients.”
ResultMari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., Rosenstock, J., & For the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345
Ahrén, B., Pacini, G., Foley, J. E., & Schweizer, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1936 · Cited by 309
Self-citationCombination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300 · cited 2×
“There are few studies of an oral agent added to insulin therapy in patients with comparable phenotype, thus direct comparisons are problematic [7].”
BackgroundAlpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., Han, J., Taylor, K., Fineman, M., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2397 · Cited by 254
Cited by
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., & Meeran, K. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 403
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305
“Different rates of hypoglycaemia have been reported with DPP-4 inhibitors when added to ongoing insulin therapy [29,30].”
BackgroundA review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Self-citationNRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Goldberg, R. B. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1531 · Cited by 197
“Most studies of the addition of oral antidiabetes therapy to insulin therapy have demonstrated either increased rates of hypoglycemia or weight gain.(17,24,27,28) In addition, the glucoselowering effect with colesevelam in the insulin combination therapy cohort occurred regardless of whether insulin was combined with…”
BackgroundInfluentialRosenstock, J., Rendell, M. S., Gross, J. L., Fleck, P. R., Wilson, C. A., & Mekki, Q. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01124.x · Cited by 189
Ahrén, B., Schweizer, A., Dejager, S., Dunning, B. E., Nilsson, P. M., Persson, M., & Foley, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2152 · Cited by 183
“However, the correlation between the suppression of the glucagon response to meal ingestion and the improved glucose tolerance after treatment with vildagliptin (9), and the observation that vildagliptin significantly reduced glycosylated hemoglobin (HbA1c) in patients with T2DM treated with high-dose ( 80 U/d) insuli…”
BackgroundInfluentialSelf-citationBarnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162
“3 (30–149) Insulin type, n (%) No pre-mixed 115 (38) 69 (46) Intermediate acting and long acting 9 (3) 8 (5) Intermediate acting, alone 54 (18) 32 (21) Long acting, alone 52 (17) 29 (19) Any pre-mixed 189 (62) 82 (54) Pre-mixed alone 182 (60) 76 (50) Intermediate acting and pre-mixed 4 (1) 4 (3) Long acting and pre-mi…”
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Self-citationIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“In addition, DPP-4 inhibitors could also be used in conjunction with insulin therapy [114].”
BackgroundLind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Metadata
- Authors
- Fonseca, V., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I., & Dejager, S.
- Venue
- Diabetologia
- Published
- 2007-03-27
- Volume
- 50
- Issue
- 6
- Pages
- 1148-1155
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1970406523
- Cited by
- 369
- References
- 17
- FWCI
- 32.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.